PSMA3 (Proteasome subunit alpha type-3) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.
Component of the 20S core proteasome complex involved in the proteolytic degradation of most intracellular proteins. This complex plays numerous essential roles within the cell by associating with different regulatory particles. Associated with two 19S regulatory particles, forms the 26S proteasome and thus participates in the ATP-dependent degradation of ubiquitinated proteins.
Open Targets scores its association with cancer at 0.63 (direct and indirect evidence; datatypes literature 0.96, genetic association 0.00, clinical 0.99).
In plain words · PSMA3 (Proteasome subunit alpha type-3) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.
PSMA3 (Proteasome subunit alpha type-3) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.
Component of the 20S core proteasome complex involved in the proteolytic degradation of most intracellular proteins. This complex plays numerous essential roles within the cell by associating with different regulatory particles.
No product in this corpus aims at PSMA3 yet. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
Broadly expressed or essential: HPA lists PSMA3 among essential proteins and finds the RNA at low tissue specificity; a medicine acting on the wild-type protein would expose normal tissue too. HPA PSMA3: RNA low tissue specificity; high antibody staining in 10 normal tissues; highest cancer staining carcinoid (1 of 3 high). Distribution: 2 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Multiple myeloma, Lymphoma); Open Targets associates it with 2 specific cancer types at or above 0.5 (plasma cell myeloma, mantle cell lymphoma). (Rule 7 of scripts/fetch-target-specificity.ts.)
Sources: Human Protein Atlas PSMA3 tissue; Open Targets ENSG00000100567 associations
First described 1991. Earliest sequence paper UniProt cites for the protein: Tamura et al, Biochim. Biophys. Acta, 1991, "Molecular cloning and sequence analysis of cDNAs for five major subunits of human proteasomes (multi-catalytic proteinase complexes)". Source.
Sources: HGNC HGNC:9532 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P25788 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000100567 (association with cancer (MONDO_0004992) 0.63; per-cancer scores at or above 0.5: plasma cell myeloma 0.62, non-Hodgkin lymphoma 0.57, mantle cell lymphoma 0.54 (GraphQL API, CC0))
Component of the 20S core proteasome complex involved in the proteolytic degradation of most intracellular proteins. This complex plays numerous essential roles within the cell by associating with different regulatory particles. Associated with two 19S regulatory particles, forms the 26S proteasome and thus participates in the ATP-dependent degradation of ubiquitinated proteins. The 26S proteasome plays a key role in the maintenance of protein homeostasis by removing misfolded or damaged proteins that could impair cellular functions, and by removing proteins whose functions are no longer required. Associated with the PA200 or PA28, the 20S proteasome mediates ubiquitin-independent protein degradation. This type of proteolysis is required in several pathways including spermatogenesis (20S-PA200 complex) or generation of a subset of MHC class I-presented antigenic peptides (20S-PA28 complex). Location: Cytoplasm; Nucleus (UniProt). Locus 14q23.1 (HGNC).
RNA: low tissue specificity, detected in all normal tissues.
Medium: Bronchus, Duodenum, Endometrium, Fallopian tube, Liver, Lung, Nasopharynx, Parathyroid gland.
Medium only: cervical cancer, colorectal cancer, lung cancer, ovarian cancer.
HPA PSMA3 tissue · HPA PSMA3 pathology · HPA protein class: Essential proteins
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"PSMA3" OR ABSTRACT:"PSMA3" OR TITLE:"proteasome 20S subunit alpha 3" OR ABSTRACT:"proteasome 20S subunit alpha 3" OR TITLE:"Proteasome subunit alpha type-3" OR ABSTRACT:"Proteasome subunit alpha type-3" OR TITLE:"HC8" OR ABSTRACT:"HC8") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about PSMA3, not a curated reading list.